Gyre Therapeutics (GYRE) News Today $7.45 +0.04 (+0.55%) As of 12:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Gyre Therapeutics (NASDAQ:GYRE) Trading Down 5.9% - Time to Sell?July 15 at 4:23 PM | marketbeat.comGyre Therapeutics: Unique Business Model, Unique ChallengesJune 30, 2025 | seekingalpha.comGYRE - Gyre Therapeutics Inc Sustainability - MorningstarJune 26, 2025 | morningstar.comMGyre Therapeutics, Inc. (GYRE) Latest Press Releases & Corporate News - Yahoo FinanceJune 24, 2025 | ca.finance.yahoo.comPublic companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19%June 20, 2025 | finance.yahoo.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 4% - Here's What HappenedJune 17, 2025 | marketbeat.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest UpdateJune 15, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 6% - What's Next?June 11, 2025 | marketbeat.comGNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in ChinaJune 11, 2025 | msn.comGyre Therapeutics Inc.: Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10, 2025 | finanznachrichten.deGyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10, 2025 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Sees Large Volume Increase - Here's WhyJune 3, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Down 7.9% - What's Next?June 3, 2025 | marketbeat.comGyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis TrialsMay 31, 2025 | finance.yahoo.comGyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis TrialsMay 30, 2025 | msn.comGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 29, 2025 | finance.yahoo.comInsider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of StockMay 29, 2025 | marketbeat.comGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesMay 29, 2025 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Sees Strong Trading Volume - Should You Buy?May 29, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - What's Next?May 28, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - What's Next?May 25, 2025 | marketbeat.comGyre Therapeutics launches public stock offeringMay 24, 2025 | investing.comGyre Therapeutics announces new stock offeringMay 24, 2025 | uk.investing.comGyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB ...May 24, 2025 | morningstar.comMGyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in Liver Fibrosis Treatment, Paving Way for NDA Submission in 2025May 24, 2025 | nasdaq.comGyre Therapeutics Announces Commencement of Underwritten Public Offering of Common StockMay 24, 2025 | nasdaq.comGyre Therapeutics Shares Fall as Stock Offering Overshadows Positive Trial DataMay 23, 2025 | marketwatch.comGyre Therapeutics Announces Proposed Underwritten Public Offering of Common StockMay 23, 2025 | finance.yahoo.comGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common StockMay 23, 2025 | finance.yahoo.comGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common StockMay 22, 2025 | globenewswire.comGyre Therapeutics Announces Proposed Underwritten Public Offering of Common StockMay 22, 2025 | globenewswire.comGyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in ChinaMay 22, 2025 | globenewswire.comMajor Exercise Alert: Weiguo Ye Exercises Options Worth $478K At Gyre TherapeuticsMay 15, 2025 | benzinga.comGyre Therapeutics (NASDAQ:GYRE) Trading 14.3% Higher - Still a Buy?May 14, 2025 | marketbeat.comGyre Therapeutics First Quarter 2025 Earnings: EPS: US$0.031 (vs US$0.09 in 1Q 2024)May 10, 2025 | finance.yahoo.comGyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | globenewswire.comA Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To EquityMay 7, 2025 | finance.yahoo.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 5.9% - Here's WhyMay 7, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Hits New 12-Month High - Still a Buy?May 3, 2025 | marketbeat.comGyre Therapeutics (GYRE) to Release Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 5% - Time to Buy?April 30, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Up 4.7% - Time to Buy?April 17, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Hits New 12-Month Low - Here's WhyApril 12, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 11.9% - What's Next?April 11, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Up 13.3% - Here's What HappenedApril 10, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 10.5% - Here's WhyApril 4, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low - Here's WhyApril 2, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% - Time to Sell?April 1, 2025 | marketbeat.comGyre Therapeutics announces NMPA approval for trial on pirfenidoneMarch 31, 2025 | markets.businessinsider.comGyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary ComplicationsMarch 31, 2025 | globenewswire.com Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address GYRE Media Mentions By Week GYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GYRE News Sentiment▼0.930.96▲Average Medical News Sentiment GYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GYRE Articles This Week▼22▲GYRE Articles Average Week Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kymera Therapeutics News Today Immunovant News Today MorphoSys News Today Crinetics Pharmaceuticals News Today Alvotech News Today HUTCHMED News Today Amneal Pharmaceuticals News Today Catalyst Pharmaceuticals News Today Bausch Health Cos News Today Organon & Co. News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GYRE) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
